商品名 スンベプラ 。
May 5, 2015 · Interventions: All patients received twice-daily treatment with the fixed-dose combination of daclatasvir (30 mg), asunaprevir (200 mg), and beclabuvir (75 mg)
This study aimed to evaluate the long‐term clinical course of patients achieving a sustained virologic response (SVR) with daclatasvir plus asunaprevir (DCV/ASV) therapy
In this prospective, multicenter study, we evaluated the efficacy and safety of daclatasvir and asunaprevir combination therapy, with a focus on patients with renal
Interventions Patients received a twice-daily fixed-dose combination of daclatasvir, 30 mg; asunaprevir, 200 mg; and beclabuvir, 75 mg
Daclatasvir with asunaprevir was a safe treatment, even in patients aged ≥75 years
Daclatasvir has been approved for use in combination with other drugs, such as sofosbuvir and asunaprevir, in patients with compensated liver disease (including
It was undergoing development by Bristol-Myers Squibb and has completed Daclatasvir (DCV)—the benchmark pangenotypic nonstructural protein 5A inhibitor—has been shown to be efficacious and generally well tolerated in partnership with other HCV direct-acting antivirals, including sofosbuvir, asunaprevir (ASV), and ASV plus beclabuvir
Importance: The antiviral activity of all-oral, ribavirin-free, direct-acting antiviral regimens requires evaluation in patients with chronic hepatitis C virus (HCV) infection
0 log copies/mL at that time
Sofosbuvir is a nucleotide analog inhibitor of HCV NS5B, an RNA-dependent RNA polymerase, which is the key enzyme mediating HCV RNA replication
The population pharmacokinetics (popPK) of daclatasvir and asunaprevir were characterized by nonlinear mixed-effects modeling using 3801 and 2626 concentration data from 336 and 265 Japanese HCV subjects, respectively
78 Most adverse events were mild or moderate
Since 2013, several new generation DAAs have been approved for the treatment of HCV
Importance: Effective and well-tolerated, interferon-free regimens are needed for treatment of patients with chronic hepatitis C virus (HCV) infection and cirrhosis
アスナプレビル (Asunaprevir)は C型肝炎 経口治療薬の一つである。
We evaluated the efficacy and safety of DCV and ASV combination therapy for patients with chronic hepatitis C virus (HCV) genotype
Erythema multiforme has been reported with this drug as part of an asunaprevir regimen